BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8626823)

  • 1. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
    Ringel MD; Ladenson PW
    J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
    Robbins RJ; Driedger A; Magner J;
    Thyroid; 2006 Nov; 16(11):1121-30. PubMed ID: 17123339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
    Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
    Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma.
    Löffler M; Weckesser M; Franzius C; Kies P; Schober O
    Nuklearmedizin; 2003 Dec; 42(6):240-3. PubMed ID: 14668956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
    Ladenson PW; Braverman LE; Mazzaferri EL; Brucker-Davis F; Cooper DS; Garber JR; Wondisford FE; Davies TF; DeGroot LJ; Daniels GH; Ross DS; Weintraub BD
    N Engl J Med; 1997 Sep; 337(13):888-96. PubMed ID: 9302303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
    Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
    Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
    Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
    Gómez Camarero P; Martínez Brocca MA; Rodríguez Rodríguez JR; Navarro González E; Tirado Hospital JL; González Duarte D; Vázquez Albertino R; Astorga Jimenez R
    Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
    Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant humane thyrotropin (rhtSH) a new aid in the diagnosis and treatment of thyroid carcinoma with radio-iodine.
    Brans B; Gemmel F; De Winter O; Fiers T; De Roose J; Vermeersch H; Rubens R; Kaufman JM; Dierckx RA
    Acta Clin Belg; 2001; 56(5):316-20. PubMed ID: 11770226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary thyroid carcinoma metastatic to the pituitary gland.
    Masiukiewicz US; Nakchbandi IA; Stewart AF; Inzucchi SE
    Thyroid; 1999 Oct; 9(10):1023-7. PubMed ID: 10560958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
    Perros P
    J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for the combined diagnostic and therapeutic use of recombinant human thyroid-stimulating hormone.
    Serafini AN; Clauss RP; Levis-Dusseau S
    Clin Nucl Med; 2003 Jan; 28(1):14-7. PubMed ID: 12493954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
    Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
    J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.
    Bacher R; Hohberg M; Dietlein M; Wild M; Kobe C; Drzezga A; Schmidt M
    J Nucl Med; 2019 May; 60(5):631-637. PubMed ID: 30315143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.